\chapter{Simulation of different vaccination strategies in girls and boys with the aim to eradicate the HPV oncogenic HR}\label{vaccinationStrategies}
In this Chapter, we are going to simulate the scenarios where we vaccinate GARDASIL9 to boys and girls with a coverage of $60\%$, $75\%$ and $90\%$. Then, we will see when a decline of $65\%$, $75\%$, $85\%$ and $95\%$ is reached in all the cases for HPV oncogenic HR. Our results will be compared with the ones in \cite{Brisson2016}, where the authors consider that the elimination of the HPV HR included in GARDASIL9 (the oncogenic ones) will be reached after $80$ years vaccinating boys and girls with a coverage of $80\%$. The results can be seen in Table \ref{tabla:decline_HR_onco}.

\begin{table}[!h]
	\hspace*{-6em}%me lo saco de la manga de Internet
	\centering
	\small
	\begin{tabular}{c|lll}
        \\
        \hline
        \multicolumn{4}{c}{\textbf{Vaccination of boys and girls with a coverage of $60\%$}}\\
        \hline
        Decline & Women &  Men & MSM \\ 
        \hline		
$ 65 \%$ & year  2040 , CI95\% $[ 2029 , 2051 ]$ & year  2047, CI95\% $[ 2031 , 2053 ]$ & year $-$ , CI95\% $[ 2055, - ]$ \\
$ 75 \%$ & year  2050 , CI95\% $[ 2032 , 2055 ]$ & year  2105 , CI95\% $[ 2053 , 2073 ]$ & year  $-$ , CI95\% $[ - , - ]$ \\
$ 85 \%$ & year  2084 , CI95\% $[ 2073 , - ]$ & year  $-$ , CI95\% $[ - , - ]$ & year  $-$, CI95\% $[ - , - ]$ \\
$ 95 \%$ & year  $-$ , CI95\% $[ - , - ]$ & year  $-$ , CI95\% $[ - , - ]$ & year  $-$ , CI95\% $[ - , - ]$ \\
		\\
		\hline 		
		\multicolumn{4}{c}{\textbf{Vaccination of boys and girls with a coverage of $75\%$}}\\
		\hline
		Decline & Women &  Men & MSM \\ 
		\hline 
$ 65 \%$ & year  2034 , CI95\% $[ 2028 , 2047 ]$ & year  2039 , CI95\% $[ 2028 , 2048 ]$ & year  2045 , CI95\% $[ 2042 , 2049 ]$ \\
$ 75 \%$ & year  2042 , CI95\% $[ 2030 , 2050 ]$ & year  2046 , CI95\% $[ 2032 , 2052 ]$ & year  2053 , CI95\% $[ 2049 , 2108 ]$ \\
$ 85 \%$ & year  2050 , CI95\% $[ 2033 , 2054 ]$ & year  2054 , CI95\% $[ 2042 , 2056 ]$ & year  $-$ , CI95\% $[ - , - ]$ \\
$ 95 \%$ & year  $-$ , CI95\% $[ 2060 , - ]$ & year  $-$ , CI95\% $[ - , - ]$ & year  $-$ , CI95\% $[ - , - ]$ \\
         \\
         \hline
         \multicolumn{4}{c}{\textbf{Vaccination of boys and girls with a coverage of $90\%$}}\\
         \hline
         Decline & Women &  Men & MSM \\ 
         \hline
$ 65 \%$ & year  2032 , CI95\% $[ 2027 , 2046 ]$ & year  2035 , CI95\% $[ 2027 , 2046 ]$ & year  2039 , CI95\% $[ 2036 , 2042 ]$ \\
$ 75 \%$ & year  2038 , CI95\% $[ 2029 , 2050 ]$ & year  2041 , CI95\% $[ 2030 , 2049 ]$ & year  2044 , CI95\% $[ 2041 , 2047 ]$ \\
$ 85 \%$ & year  2046 , CI95\% $[ 2032 , 2052 ]$ & year  2048 , CI95\% $[ 2033 , 2052 ]$ & year  2050 , CI95\% $[ 2047 , 2052 ]$ \\
$ 95 \%$ & year  2054 , CI95\% $[ 2042 , 2056 ]$ & year  2055 , CI95\% $[ 2048 , 2057 ]$ & year  $-$ , CI95\% $[ 2107 , - ]$
	\end{tabular} 
	\caption{Here, we show when a decline of HPV oncogenic HR of $65\%$, $75\%$, $85\%$ and $95\%$ is reached when vaccinating boys and girls with a coverage of $60\%$, $75\%$ and $90\%$. MSM are included in men, and also considered separately.}
	\label{tabla:decline_HR_onco}
\end{table}

Now, in Figure \ref{fig:erradicacion}, we show some graphs about the decline of HPV oncogenic in 14-64 years old women, men and MSM with coverage for women and men of $75\%$ and $90\%$.

\begin{figure}[!]
	\centering
	\begin{tabular}{cc}
		\includegraphics[width=0.5\linewidth]{IMGs/7.-Erradicacion_ONCO/Decl_muj_14_64_onco_75_75.pdf}	& 
		\includegraphics[width=0.5\linewidth]{IMGs/7.-Erradicacion_ONCO/Decl_muj_14_64_onco_90_90.pdf}  \\ 
		Decline. Women. Coverage $75\%$	& Decline. Women. Coverage $90\%$ \\ 
		\includegraphics[width=0.5\linewidth]{IMGs/7.-Erradicacion_ONCO/Decl_hom_14_64_onco_75_75.pdf}	& 
		\includegraphics[width=0.5\linewidth]{IMGs/7.-Erradicacion_ONCO/Decl_hom_14_64_onco_90_90.pdf}  \\ 
		Decline. Men. Coverage $75\%$	& Decline. Men. Coverage $90\%$ \\ 		
		\includegraphics[width=0.5\linewidth]{IMGs/7.-Erradicacion_ONCO/Decl_MSM_14_64_onco_75_75.pdf}	& 
		\includegraphics[width=0.5\linewidth]{IMGs/7.-Erradicacion_ONCO/Decl_MSM_14_64_onco_90_90.pdf}  \\ 
		Decline. MSM. Coverage $75\%$	& Decline. MSM. Coverage $90\%$
	\end{tabular} 
	\caption{Decline of HPV oncogenic in 14-64 years old women, men and MSM with coverage for women and men of $75\%$ and $90\%$ over the time. The horizontal dashed lines point out the decline percentages of $65\%$, $75\%$, $85\%$ and $95\%$.}
	\label{fig:erradicacion}
\end{figure}

As we can see in the Figure \ref{fig:erradicacion}, the highest values of decline are reached around $2060$ in all the graphs, that is after a complete generation has been vaccinated. Therefore, a high coverage for women and men during a whole generation has to be considered if we want to eradicate the cancer produced by HPV oncogenic. 
